ReviewFrontiers in cell and developmental biology2025
Mechanisms and therapeutic prospects of hypoxia-inducible factor 1-alpha in acute kidney injury: a systematic review.
Review in Frontiers in cell and developmental biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- The mechanism and therapeutic prospect of HIF-1 α/BNIP3 pathway in regulating mitophagy in tubulointerstitial fibrosis.Renal failure · 2026Review
- The Lung-Kidney Axis: A Coordinated Regulation of Oxygen Sensing and Erythropoiesis.Biomedicines · 2026Review
- The Current Application Prospects of Nanomedicine in Renal Ischemia-Reperfusion Injury.International journal of nanomedicine · 2026Review
- Pathological triad of perioperative acute kidney injury: renal microcirculatory hypoxia, mitochondrial damage, and immuno-metabolic reprogramming.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Acute Kidney Injury (AKI) poses a significant global health challenge, with increasing incidence and mortality rates, and profoundly impacts long-term outcomes, including progression to chronic kidney disease. Ischemia-reperfusion injury (IRI) is a major cause of AKI, in which hypoxia-inducible factor-1α (HIF-1α) plays a complex and dual role. Methods: This review systematically analyzes the regulatory functions of HIF-1α in renal IRI, focusing on molecular mechanisms involving oxidative stress, apoptosis, inflammation, and tissue repair. Results: Emerging evidence from preclinical studies demonstrates that HIF-1α orchestrates key adaptive responses in renal IRI, including the regulation of mitophagy, management of endoplasmic reticulum stress, and induction of metabolic reprogramming toward glycolysis. Conclusion: Targeting HIF-1α represents a promising therapeutic strategy for AKI. Advances in HIF-1α-modulating therapies, particularly HIF prolyl hydroxylase inhibitors, offer novel avenues for both prevention and treatment. These findings underscore the potential for HIF-1α-centered therapies to mitigate AKI progression and improve clinical outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.